PL372719A1 - Long pentraxin ptx3 functional derivatives for preparing an autologous vaccine for the treatment of tumours - Google Patents

Long pentraxin ptx3 functional derivatives for preparing an autologous vaccine for the treatment of tumours

Info

Publication number
PL372719A1
PL372719A1 PL03372719A PL37271903A PL372719A1 PL 372719 A1 PL372719 A1 PL 372719A1 PL 03372719 A PL03372719 A PL 03372719A PL 37271903 A PL37271903 A PL 37271903A PL 372719 A1 PL372719 A1 PL 372719A1
Authority
PL
Poland
Prior art keywords
tumours
preparing
treatment
functional derivatives
long pentraxin
Prior art date
Application number
PL03372719A
Other languages
English (en)
Polish (pl)
Inventor
Santis Rita De
Giovanni Salvatori
Original Assignee
Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. filed Critical Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.
Publication of PL372719A1 publication Critical patent/PL372719A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL03372719A 2002-02-28 2003-02-25 Long pentraxin ptx3 functional derivatives for preparing an autologous vaccine for the treatment of tumours PL372719A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2002RM000109A ITRM20020109A1 (it) 2002-02-28 2002-02-28 Derivati funzionali della pentraxina lunga ptx3 per preparare un vaccino autologo per la cura dei tumori.

Publications (1)

Publication Number Publication Date
PL372719A1 true PL372719A1 (en) 2005-07-25

Family

ID=11456119

Family Applications (1)

Application Number Title Priority Date Filing Date
PL03372719A PL372719A1 (en) 2002-02-28 2003-02-25 Long pentraxin ptx3 functional derivatives for preparing an autologous vaccine for the treatment of tumours

Country Status (12)

Country Link
US (1) US20090110666A1 (enExample)
EP (1) EP1478661A2 (enExample)
JP (1) JP2005538690A (enExample)
KR (1) KR20040099291A (enExample)
AR (1) AR038854A1 (enExample)
AU (1) AU2003214645A1 (enExample)
CA (1) CA2475526A1 (enExample)
IT (1) ITRM20020109A1 (enExample)
MX (1) MXPA04008217A (enExample)
PL (1) PL372719A1 (enExample)
TW (1) TWI293958B (enExample)
WO (1) WO2003072603A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20040858A1 (it) 2004-04-29 2004-07-29 Farma Dev S R L Anticorpi monoclonali ibridomi metodo migliorato per determinare la proteina ptx3 e kit per detta determinazione
ITRM20040489A1 (it) * 2004-10-08 2005-01-08 Sigma Tau Ind Farmaceuti Pentraxina lunga ptx3 deglicosilata o desialidata.
SI1973944T1 (sl) * 2006-01-24 2016-07-29 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. FGF2 vezavni peptidi in njihova uporaba
US9226960B2 (en) 2010-04-16 2016-01-05 Andrew B. Bush FGF modulation of in vivo antibody production and humoral immunity
US8435525B1 (en) * 2010-04-16 2013-05-07 Andrew B. Bush FGF modulation of in vivo antibody production and humoral immunity
TWI531375B (zh) 2015-05-29 2016-05-01 國立成功大學 抑制癌細胞活性之短肽治療劑及含此之醫藥組成物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849478A (en) * 1986-08-14 1998-12-15 Cashman; Daniel P. Blocked-polymerase polynucleotide immunoassay method and kit
US5290551A (en) * 1990-05-08 1994-03-01 Thomas Jefferson University Treatment of melanoma with a vaccine comprising irradiated autologous melanoma tumor cells conjugated to a hapten
IT1298487B1 (it) * 1997-12-19 2000-01-10 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,
IT1317927B1 (it) * 2000-11-03 2003-07-15 Sigma Tau Ind Farmaceuti Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patologie autoimmuni.
IT1317930B1 (it) * 2000-11-08 2003-07-15 Sigma Tau Ind Farmaceuti Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patalogie associate ad una alterata attivazione
US20020122820A1 (en) * 2001-01-16 2002-09-05 Hildebrand William H. Soluble MHC artificial antigen presenting cells
AU2002324328B2 (en) * 2001-08-03 2007-09-06 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of long pentraxin PTX3 for treating female infertility
US7041648B2 (en) * 2001-08-03 2006-05-09 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Compositions and methods for treating female fertility
ITRM20020191A1 (it) * 2002-04-08 2003-10-08 Sigma Tau Ind Farmaceuti Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patologie tumorali associate ad una alterata att
US20040137544A1 (en) * 2002-10-31 2004-07-15 Roberto Latini PTX3 as an early prognostic indicator of cardiovascular and cerebrovascular pathologies
ITRM20030596A1 (it) * 2003-12-23 2005-06-24 Sigma Tau Ind Farmaceuti Uso di inibitori della pentraxina lunga ptx3, per la preparazione di un medicamento per la prevenzione e cura di patologie che rispondono all'inibizione dell'attivita' biologica di detta ptx3.
US20070023879A1 (en) * 2005-07-29 2007-02-01 Vinayak Pandey Single unit heat sink, voltage regulator, and package solution for an integrated circuit

Also Published As

Publication number Publication date
TW200303755A (en) 2003-09-16
EP1478661A2 (en) 2004-11-24
WO2003072603A2 (en) 2003-09-04
CA2475526A1 (en) 2003-09-04
WO2003072603A3 (en) 2004-03-18
US20090110666A1 (en) 2009-04-30
AR038854A1 (es) 2005-01-26
MXPA04008217A (es) 2004-11-26
WO2003072603A9 (en) 2004-10-07
AU2003214645A1 (en) 2003-09-09
AU2003214645A8 (en) 2003-09-09
KR20040099291A (ko) 2004-11-26
ITRM20020109A0 (it) 2002-02-28
ITRM20020109A1 (it) 2003-08-28
TWI293958B (en) 2008-03-01
JP2005538690A (ja) 2005-12-22

Similar Documents

Publication Publication Date Title
AP2005003283A0 (en) Indole derivatives useful for the treatment os diseases
IL206984A0 (en) Analoges of benzoquinone-containing ansamycins for the treatment of cancer
EP1624932A4 (en) APPARATUS FOR ADMINISTERING LIGHT STIMULATION
EP1747039A4 (en) PARTIALLY IMPLANTABLE SYSTEM FOR ELECTRICALLY TREATING CANCER
IL189657A (en) Process for the preparation of n-phenyl-2-pyrimidine-amine derivatives
AU2003239932A8 (en) Tetravalent dengue vaccines
PL378108A1 (pl) Leczenie łączone do terapii zapalnych zaburzeń immunologicznych
IL175373A0 (en) The use of anti biotics as vaccine adjuvants
PL376454A1 (en) 1-acyl-pyrrolidine derivatives for the treatment of viral infections
SI1660009T1 (sl) Metode za zdravljenje endometrioze
AP2006003537A0 (en) Use of polypeptides of the cupredoxin family in cancer therapy.
AU2003290059A8 (en) Use of cd137 antagonists for the treatment of tumors
IL175749A0 (en) Chaperone - based therapy for niemann-pick disease
IL140796A0 (en) An autologous anti-cancer vaccine
AU2003285320A8 (en) Vaccine
AU2003214645A8 (en) Long pentraxin ptx3 functional derivatives for preparing an autologous vaccine for the treatment of tumours
IL162818A0 (en) Combination therapy for the treatment of bacterialinfections
SE0202318L (sv) Anordning vid två eller flera implantat försedda med tillväxtstimulerande substans(-er)
AU2003226899A8 (en) Human diabetes-mediating proteins
AU2003220567A8 (en) Compostions for darkening the skin
GB0209878D0 (en) Vaccine
EP1599170A4 (en) VACCINE ADJUVANT BASED ON HUMAN LYMPHOCYTES
ZA200505996B (en) Combination therapy for the treatment of immunoinflammatory disorders
TWI350174B (en) Adjuvanted bovine vaccines
GB0308691D0 (en) Vaccine preparations

Legal Events

Date Code Title Description
DISC Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)